Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

838

Enrollment

NETWORK

Sponsor class

Conditions

Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions

DRUG: Chemotherapy
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Ramucirumab

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]
[object Object]
[object Object]